Literature DB >> 12389822

Rhabdomyolysis and cerivastatin: was it a problem of dose?

Dipen Kalaria, Willem Wassenaar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12389822      PMCID： PMC126482     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Cerivastatin and reports of fatal rhabdomyolysis.

Authors:  Judy A Staffa; Jennie Chang; Lanh Green
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

2.  Bayer pulls cerivastatin (Baycol) from market.

Authors:  E Wooltorton
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262
  2 in total
  3 in total

1.  Cerivastatin Nanoliposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Young Lee; S Balakrishna Pai; Ravi V Bellamkonda; David H Thompson; Jaipal Singh
Journal:  J Pharmacol Exp Ther       Date:  2018-04-25       Impact factor: 4.030

2.  Dihydroaustrasulfone Alcohol (WA-25) Impedes Macrophage Foam Cell Formation by Regulating the Transforming Growth Factor-β1 Pathway.

Authors:  Yi-Chen Wang; Han-Chun Hung; Chien-Wei Feng; Shi-Ying Huang; Chun-Hong Chen; Yen-You Lin; Yao-Chang Chen; San-Nan Yang; Jui-Hsin Su; Jyh-Horng Sheu; Zhi-Hong Wen
Journal:  Int J Mol Sci       Date:  2015-05-07       Impact factor: 5.923

Review 3.  Statins, Muscle Disease and Mitochondria.

Authors:  Radha Ramachandran; Anthony S Wierzbicki
Journal:  J Clin Med       Date:  2017-07-25       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.